Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan in Ambulatory Heart Failure
NCT04705337Phase 4Terminated
- Sponsor
- Medical University of Białystok
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of levosimendan in heart failure with reduced ejection fraction (HFrEF), sponsored by Medical University of Białystok. Started Dec 2021; status: terminated.
02
Drugs
levosimendan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04705337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705337.